An Exploratory Study to Evaluate Safety and Efficacy of the Neoantigen Personalized mRNA Vaccine AK154 Monotherapy or in Combination With AK104 or AK112,and the Sequential mFOLFIRINOX Regimen as Adjuvant Therapy in Surgically Resectable Pancreatic Ductal Adenocarcinoma

To explore safety and efficacy of neoantigen personalized mRNA vaccines AK154 monotherapy or in combination with AK104/AK112 and sequential mFOLFIRINOX regime in Resected PDAC

开始日期2025-07-22

申办/合作机构

中山康方生物医药有限公司

[+1]

NCT07023315

/ Not yet recruiting临床3期

A Randomized, Double-blind, Phase III Clinical Study Comparing the Efficacy and Safety of Cadonilimab Plus Oxaliplatin and Tegafur-Gimeracil-Oteracil Potassium (SOX) Versus Placebo Plus SOX as Perioperative Treatment for Patients With Resectable Gastric and Gastroesophageal Junction (G/GEJ) Adenocarcinoma

This study investigates treatment of cadonilimab or placebo combined with SOX chemotherapy (oxaliplatin + tegafur-gimeracil-oteracil potassium) given before surgery (neoadjuvant) and cadonilimab or placebo combined with SOX chemotherapy after surgery (adjuvant), will work and be safe for the treatment of resectable (removable by surgery) gastric or gastroesophageal cancer.

开始日期2025-07-01

申办/合作机构

中山康方生物医药有限公司

NCT06984718

/ Not yet recruiting临床2期

A Phase II, Randomized, Open-label, Multi-center Study of AK104 in Combination With Lenvatinib Versus Lenvatinib in Patients With Advanced Hepatocellular Carcinoma Who Have Progressed on Atezolizumab and Bevacizumab

This is a Phase II, randomized, open-label, global, multi-center study to compare the efficacy and safety of AK104 in combination with lenvatinib versus lenvatinib in patients with advanced hepatocellular carcinoma who have progressed on the first line treatment of atezolizumab and bevacizumab.

开始日期2025-06-25

申办/合作机构

中山康方生物医药有限公司

100 项与卡度尼利单抗相关的临床结果

登录后查看更多信息

100 项与卡度尼利单抗相关的转化医学

登录后查看更多信息

100 项与卡度尼利单抗相关的专利（医药）

登录后查看更多信息

264

项与卡度尼利单抗相关的文献（医药）

2025-12-31·Journal of Pharmaceutical Policy and Practice

Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial

Article

作者: Wang, Jinglin ; Wang, Chunping ; Zhang, Qilin ; Ding, Yiling ; Shu, Yamin

Background:

The addition of cadonilimab to first-line platinum-based chemotherapy with or without bevacizumab significantly improved progression-free survival (PFS) and overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer. However, the economic value of using this novel therapy for this indication is currently unknown. The aim of this study is to evaluate the cost-effectiveness of the addition of cadonilimab to first-line standard chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer from the perspective of Chinese healthcare system.

Methods:

A partitioned survival model was constructed to compare the cost-effectiveness of cadonilimab versus placebo in patients enrolled in the COMPASSION-16 trial. Cost, life-year, quality-adjusted life-year (QALY), incremental cost-effectiveness ratio (ICER), incremental net health benefit (INHB), and incremental net monetary benefit (INMB) were calculated for 2 treatment strategies. Sensitivity, scenario, and subgroup analyses, and value of information analysis (EVPI) were performed.

Results:

Cadonilimab provided an additional 1.18 QALYs and $89,528.64 compared with placebo, which resulted in an ICER of $75,944.56/QALY. At the willingness-to-pay threshold of $38,042.49/QALY, INHB was estimated to be -1.17 QALYs, while INMB amounted to -$44,681.55 and EVPI was calculated as $71.40/person. Sensitivity analyses revealed that the model was most sensitive to hazard ratio (HR) for OS and PFS, and the probability of cadonilimab being cost-effective was 0.70%. To achieve cost-effectiveness, the price of cadonilimab must be reduced by approximately 50%. Subgroup analysis found that all subgroups unfavored cadonilimab by varying the HR for OS and PFS. Scenario analyses showed using life-year as effectiveness, altering time horizon and selection of survival analysis did not reverse results.

Conclusions:

Although the use of cadonilimab resulted in clinical benefit, it was not deemed cost-effective as a first-line therapy for persistent, recurrent, or metastatic cervical cancer in China. Lowering the price of cadonilimab may enhance its cost-effectiveness.

2025-05-01·BMJ Open

Efficacy and safety of cadonilimab combined with chemotherapy as the first-line treatment for primary advanced or recurrent endometrial cancer: a prospective single-arm open-label phase II clinical trial

Article

作者: Chen, Xiaoxiang ; Liu, Tongyu ; Lin, Yingtao ; Lin, Jie ; Chen, Jian ; Jiang, Yu ; Sun, Yang ; Zou, Jianping ; Li, Yuzhi ; Tu, Chunhua ; Zhuo, Yanhong ; Liu, Bin ; Yang, Linlin ; Chen, Lijun

Introduction:

Recently, immunotherapy has significantly transformed the treatment landscape of endometrial cancer (EC). Results from KEYNOTE-158, RUBY and AtTEnd showed programmed cell death 1 (PD-1) or programmed cell death-ligand 1 inhibitors with promising efficacy in primary advanced or recurrent EC. However, few studies focused on the role of dual immune checkpoints in primary advanced or recurrent EC. Cadonilimab is an immune checkpoint inhibitor targeting the PD-1 and T-lymphocyte antigen-4, which is expected to show substantial clinical efficacy in EC. Combining cadonilimab with standard chemotherapy may have synergistic effects, making this combination a promising first-line treatment for primary advanced or recurrent EC. Furthermore, incorporating molecular classification for guidance on the use of cadonilimab may hold valuable clinical benefits.

Methods and analysis:

In this multicentre, open-label, phase II study, patients with histologically confirmed EC were eligible. Forty-five patients will be recruited. Seventeen patients will be enrolled in stage I, and at least seven cases of complete response (CR) and partial response (PR) should be observed before entering stage II. All patients will receive cadonilimab at a dosage of 10 mg/kg along with carboplatin (area under the curve (AUC)=4–5) plus paclitaxel (175 mg/m2) every 3 weeks (Q3W) for 6–8 cycles. Subsequently, patients with CR, PR or stable disease will receive maintenance of cadonilimab at 10 mg/kg Q3W for 24 months or until progressive disease or adverse events are reported. The objective response rate is the primary endpoint. The secondary endpoints include the disease control rate, duration of response, progression-free survival, overall survival and safety. Additionally, exploratory endpoints involve biomarkers that may predict the efficacy of cadonilimab and chemotherapy, as well as their relationship with molecular classifications. The interim analysis will be conducted after 17 patients have been enrolled.

Ethics and dissemination:

The study protocol meets the approval of the ethical committee of Fujian Cancer Hospital (K2023-173-04) and all other participating hospitals. Study findings will be disseminated in peer-reviewed publications.

Trial registration number:

NCT06066216.

2025-04-18·ANGLE ORTHODONTIST

Effects of chemotherapeutic vs regular toothpastes on dental plaque and gingival inflammation in orthodontic patients with fixed appliances: a systematic review and meta-analysis

Article

作者: Liu, Yinli ; Jonkman, Ronald Edwin Gaston ; Slot, Dagmar Else ; Valkenburg, Cees

ABSTRACT:

Objectives:

To analyze, appraise, and synthesize papers in which authors have compared the effects of chemotherapeutic toothpaste (CTP) and regular toothpaste (RTP) on plaque scores (PSs), gingival scores (GSs), and bleeding scores (BSs) in orthodontic patients wearing fixed appliances (FAs).

Materials and Methods:

PubMed-MEDLINE, Cochrane-CENTRAL, and Embase databases were searched with predefined search terms until April 2024 for controlled or randomized controlled clinical trials aligning with the aim. In the eligible papers, risk of bias was evaluated, data of interest were extracted, and a descriptive analysis was performed. If possible, meta-analyses and subanalyses on specific factors were conducted. The quality of evidence and strength of the recommendation were rated.

Results:

In our search and selection, we obtained five papers describing eight comparisons. Potential risk of bias was assessed as some concerns to high, and heterogeneity was considered substantial. Descriptive analysis revealed no significant difference in PS and BS, with an improvement in GS favoring CTP. Meta-analyses of the end scores showed CTP significantly reduced PS (standardized mean difference [SMD] = −0.26; 95% confidence interval [CI] = −0.52, −0.01; P = .04). However, no significant effects were observed on GS and BS. These findings were supported by the subanalyses on CTP with chlorhexidine (CHX; PS: mean difference [MD] = −5.12; 95% CI = −10.08, −0.15; P = .04). The quality of evidence was graded as very low, and strength of the recommendation was judged as very weak.

Conclusions:

For orthodontic patients with FAs, very weak certainty exists in recommending CTP (eg, with CHX) over RTP for use with toothbrushing. CTP may have a very small effect on PS and a small effect on GS.

822

项与卡度尼利单抗相关的新闻（医药）

2025-06-17

·康方生物Akeso

ASCO 2025|COMPASSION-16亚组数据更新，卡度尼利单抗联合方案一线治疗宫颈癌全面获益，引领免疫治疗2.0时代

卡度尼利单抗作为全球首个靶向PD-1/CTLA-4的肿瘤免疫双特异性抗体，2022年6月获中国NMPA批准用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌。值得庆贺的是，2025年6月4日NMPA官网正式公示，已于5月27日批准卡度尼利单抗加含铂化疗联合/不联合贝伐珠单抗用于一线治疗持续、复发或转移性宫颈癌治疗。其获批关键研究：COMPASSION-16为一项中国随机、双盲、安慰剂对照的Ⅲ期临床研究，旨在研究卡度尼利单抗联合含铂化疗联合或不联合贝伐珠单抗用于持续、复发或转移性宫颈癌一线治疗，初步研究数据于2024年IGCS大会口头汇报，作为中国妇瘤领域首个登顶《柳叶刀》主刊的研究，卡度尼利单抗联合方案为复发或转移性宫颈癌一线治疗带来重大突破。此次ASCO大会来自复旦大学附属肿瘤医院吴小华教授口头报告COMPASSION-16研究亚组数据，中国方案再次闪耀国际舞台，值此重要时刻，中国医学论坛报特邀COMPASSION-16研究主PI吴小华教授分享最新研究成果。吴小华教授专访视频2024年IGCS已公布COMPASSION-16研究初步结果，在此次ASCO大会上 COMPASSION-16研究数据更新呈现出哪些更深入、更具突破性的亮点，这些亮点对于宫颈癌治疗领域有着怎样的重要意义和潜在影响？吴小华教授复旦大学附属肿瘤医院COMPASSION-16研究是一项针对445例未接受过系统治疗的持续性、复发性或转移性宫颈癌患者，探究卡度尼利单抗对比安慰剂联合化疗±贝伐珠单抗一线治疗的有效性与安全性，主要终点为BICR评估的PFS和OS。2024年IGCS公布的初步结果令人瞩目，卡度尼利单抗联合方案显著延长患者PFS，疾病进展或死亡的风险降低38%（mPFS：13.3个月 vs 8.2个月，HR=0.62）。图1 COMPASSION-16研究PFS数据尽管mOS尚未到达，但已显现出明显获益，且近2/3患者生存超2年，24个月OS率为62.6%（vs 48.4%），死亡风险降低36%（HR：0.64，95% CI：0.48~0.86, P=0.0011）。图2 COMPASSION-16研究OS数据此外，COMPASSION-16研究结果显示卡度尼利单抗联合方案可有效提高肿瘤缓解率，其中ITT人群ORR高达82.9%（vs 68.6%），CR患者比例达35.6%（vs 22.9%），超1/3患者达到肿瘤完全缓解，mDoR为13.2个月（vs 8.2个月），在安全性方面，≥3级irAEs发生率仅为9.7%，证实了双抗联合方案在复发或转移宫颈癌一线治疗中的优势，不仅高效安全且获益持久。尤为关键的是，卡度尼利单抗治疗组获益不受PD-L1表达状态限制，联合或不联合贝伐珠单抗均能获益。图3 COMPASSION-16研究有效性BICR评估而此次ASCO大会更新的亚组分析进一步验证了卡度尼利单抗在复发或转移性宫颈癌一线治疗中的全人群获益潜力，并细化关键亚组的疗效特征。亚组分析结果展现出与整体人群一致的生存获益。无论患者年龄如何，卡度尼利单抗均显著延长患者PFS和OS，其中≥65岁老年人群获益尤为突出（PFS HR=0.39，OS HR=0.49），mOS达26.6个月（vs 15.1个月），安全性可控。图4 COMPASSION-16研究亚组分析—年龄且无论是否接受过同步放化疗（CCRT），卡度尼利单抗均显示生存优势。对于既往未接受CCRT治疗的患者，加用卡度尼利单抗后mPFS可达12个月，mOS为27个月，而对照组mPFS仅8.5个月（HR：0.67,95%CI：0.49~0.93）及mOS 24.5个月（HR：0.76,95%CI：0.52~1.12），提示卡度尼利单抗疗效不受既往CCRT治疗影响；其中既往接受CCRT的患者获益更显著，mPFS翻倍至16.1个月（vs 7.9个月），疾病进展或死亡风险降低45%。图5 COMPASSION-16研究亚组分析—既往CCRT而针对约40%不适合贝伐珠单抗治疗的患者，卡度尼利单抗联合化疗仍可大幅降低死亡风险达50%（mOS 28.2个月 vs 15.1个月），突破传统化疗治疗方案的生存局限。图6 COMPASSION-16研究亚组分析—贝伐珠单抗使用此外，研究结果还显示，以顺铂为基础化疗的患者获益更优（OS HR=0.43），尽管卡铂治疗OS HR接近临界值（0.82），但PFS仍显著延长，提示卡度尼利单抗与不同化疗方案均具有协同效应。图7 COMPASSION-16研究亚组分析—铂类化疗使用此次ASCO大会更新的研究数据不仅证实卡度尼利单抗的广泛适用性，更通过精细化亚组分析指导个体化治疗决策，为不同临床特征患者提供高效、安全的治疗选择，有望重塑复发或转移性宫颈癌一线治疗格局，推动卡度尼利单抗“全人群覆盖”临床实践探索。COMPASSION-16研究作为中国首个完全在中国入组的大三期临床研究，对中国晚期宫颈癌患者的治疗选择、临床数据填补、个体化治疗方案制定以及国际学术影响力等方面具有哪些具体意义？吴小华教授复旦大学附属肿瘤医院全球超过一半的宫颈癌病例发生在亚洲，但关于免疫检查点抑制剂PD-(L)1联合化疗±贝伐珠单抗的研究中，亚洲患者代表性不足。与KEYNOTE-826研究纳入全球人群研究不同，COMPASSION-16研究作为首个完全在中国入组的大三期研究，纳入445例中国患者，避免了因种族、地域、遗传背景等因素差异导致的结果偏差，研究结果更能准确反映中国宫颈癌患者的疾病特征、治疗反应和安全性情况，为中国宫颈癌患者提供了关键的治疗数据，有望填补中国复发转移宫颈癌一线治疗领域高质量临床数据空白，为国内临床医生提供了极具参考价值的治疗依据。此外，研究通过精细化亚组分析，进一步验证了卡度尼利单抗在不同临床特征患者中的广泛适用性。2025年ASCO更新的亚组分析进一步细化了不同临床特征患者的疗效，无论患者年龄如何、是否接受过CCRT、是否联用贝伐珠单抗治疗及使用何种化疗方案，卡度尼利单抗均可取得与全人群一致的生存获益。尤其在≥65岁、既往接受过CCRT治疗及以顺铂为基础化疗的人群中获益更为显著，为临床医生针对不同特征的宫颈癌患者制定个体化治疗方案提供了有力依据。值得一提的是，COMPASSION-16研究的结果不仅在中国具有重要意义，还在国际上得到了高度认可。作为中国妇瘤领域首次登顶《柳叶刀》主刊的研究，COMPASSION-16研究创造了我国妇科肿瘤临床研究新的辉煌，引起全球专家学者的广泛关注和热议，提升了中国在国际妇科肿瘤研究领域的影响力和话语权，进一步彰显了其国际影响力。同时，该研究在国际上的认可也提升了中国在妇科肿瘤领域的影响力，推动了国内相关医疗行业对宫颈癌免疫治疗研究和应用的重视，有望改变中国复发转移宫颈癌一线治疗的格局。卡度尼利单抗获批复发或转移性宫颈癌一线适应证对国内宫颈癌治疗格局会产生哪些革新性影响？吴小华教授复旦大学附属肿瘤医院作为首个获批宫颈癌二线治疗的双抗，2024年卡度尼利单抗成功纳入医保，进一步提升了药物治疗可及性，此次凭关键Ⅲ期临床研究COMPASSION-16获批一线适应证，则将免疫检查点抑制剂前移至复发或转移性宫颈癌初始治疗阶段，通过“早期介入”使患者在疾病负荷较轻、机体免疫功能尚未显著耗竭时即可接受卡度尼利单抗联合治疗，有望从根本上突破传统治疗的生存瓶颈。一直以来我们认为CR率可提供短期疗效的直观信号，OS则聚焦患者长期生存获益，共同为复发转移宫颈癌患者的一线治疗制定个体化治疗方案、评估预后提供关键参考，COMPASSION-16研究数据显示，卡度尼利单抗联合化疗±贝伐珠单抗治疗ITT人群CR率高达35.6%，极大程度助力实现“生存时间+生存质量”的双重治疗目标达成，为复发转移宫颈癌一线治疗提供更强缓解、更长生存的治疗方案。此外，在临床实践中，对于因基础疾病或存在出血、穿孔风险等被认为不适合使用贝伐珠单抗的患者，既往化疗、化疗+单靶点免疫检查点抑制剂治疗OS均未到达2年，而COMPASSION-16研究中，卡度尼利单抗+化疗中位OS高达28.2月，成为该类患者首个中位OS突破2年的方案。这一突破不仅是治疗方案的升级，更将推动临床生态体系变革，加速NCCN/ASCO/CACA/CSCO 等权威指南纳入卡度尼利联合方案，推动放疗与免疫治疗协同效应的临床探索，并通过“早用早获益”的循证医学证据扭转“免疫治疗仅用于后线挽救”的传统认知。随着卡度尼利单抗一线适应证落地，中国复发转移宫颈癌一线治疗将率先迈入“免疫2.0”时代，更多患者有望通过早期免疫双抗的治疗突破“5年生存率不足20%”的困境，也必将重塑复发转移宫颈癌一线治疗格局。引领“免疫2.0时代”COMPASSION-16研究是继卡度尼利单抗作为复发或转移性宫颈癌二线标准治疗后又一重大进展与突破。此次亚组分析数据再次证实，卡度尼利单抗凭借更高缓解率与更长生存期，有望助力中国复发转移宫颈癌患者一线治疗率先迈入“免疫2.0时代”。该研究结果的发布不仅为复发或转移性宫颈癌一线治疗提供新的选择，也进一步为免疫治疗在复发或转移性宫颈癌中的应用前移提供了有力的循证医学证据。此次卡度尼利单抗复发转移宫颈癌治疗一线适应证获批，将有助于更多患者从中受益！审校|复旦大学附属肿瘤医院吴小华教授整理|中国医学论坛报贺鹏转载自|中国医学论坛报今日肿瘤往期推荐产品动态一线宫颈癌全人群获批！康方生物开坦尼®获批第三项适应症产品动态依沃西一线治疗NSCLC获批上市（全球首个对比帕博利珠单抗获显著阳性结果的III期研究）产品动态美国重磅上市！派安普利单抗2个适应症获FDA批准上市，用于晚期鼻咽癌治疗产品动态康方生物爱达罗®（依若奇,IL-12/IL-23）治疗中重度斑块状银屑病适应症获批上市临床进展首个自研ADC澳洲临床入组！康方生物IO 2.0+ADC战略再进一步临床进展非肿瘤首个双抗|康方生物全球首创IL-4Rα/ST2（AK139）IND获受理，剑指呼吸系统及皮肤疾病领域临床进展依沃西方案对比替雷利珠方案1L治疗sq-NSCLC的Ⅲ期临床完成患者入组临床进展康方生物古莫奇（IL-17）单抗新药上市申请获NMPA受理数据发布荣登Nature Medicine！卡度尼利方案1L治疗胃癌Ⅲ期研究结果全文发表产品动态康方生物卡度尼利、依沃西纳入2024年国家医保目录临床进展头对头度伐利尤单抗方案，依沃西方案一线治疗胆道肿瘤III期临床完成首例患者入组临床进展全球首个CD47单抗实体瘤III期临床首例入组：依沃西联合莱法利一线治疗HNSCC（对比帕博利珠单抗）数据发布卡度尼利一线宫颈癌III期研究成果荣登《Nature Reviews Clinical Oncology》（影响因子高81.1）数据发布IGCS 2024 LBA & 《柳叶刀》主刊，卡度尼利1L宫颈癌III期研究PFS和OS双阳性结果重磅发布产品动态获FDA快速通道资格！依沃西国际多中心III期研究HARMONi完成入组，2L+EGFRm NSCLC数据发布全球首个对比帕博利珠单抗取得显著阳性结果的随机对照大III期研究——依沃西HARMONi-2重磅研究成果在WCLC发表临床进展康方生物卡度尼利联合方案治疗uHCC的III期临床研究完成首例患者入组临床进展针对PD-1/L1治疗进展晚期胃癌，卡度尼利+普络西（VEGFR-2）联合疗法Ⅲ期临床完成首例入组数据发布ASCO Oral & JAMA主刊丨Ⅲ期HARMONi-A研究重磅公布，依沃西疗法有望改变EGFR-TKI进展肺癌全球治疗标准临床进展史无前例！康方依沃西单药对比帕博利珠1L治疗PD-L1阳性NSCLC的III期临床获决定性胜出阳性结果产品动态康方生物双抗卡度尼利一线治疗晚期宫颈癌全人群的sNDA获CDE受理临床进展国际多中心注册性III期研究HARMONi-3中国启动：依沃西单抗联合化疗对比帕博利珠单抗联合化疗1L治疗sq-NSCLC产品动态高达50亿美金！康方生物与Summit就PD-1/VEGF双抗依沃西达成合作和许可协议产品动态全球首个肿瘤免疫治疗双抗——开坦尼®（PD-1/CTLA-4双抗，卡度尼利）获批上市

临床结果ASCO会议临床3期

2025-06-16

·PRNewswire

Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, in the first-line treatment of advanced, recurrent, or metastatic cervical cancer. The data was featured as an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The subgroup analysis demonstrated that cadonilimab treatment significantly improved progression-free survival (PFS) and overall survival (OS) across different patient subgroups, including: levels of PD-L1 expression, prior treatment with concurrent chemoradiotherapy (CCRT), bevacizumab use, and age of the patients (≥65, <65). These results further demonstrate the clinical value and the global women's health impact of cadonilimab in advancing thetreatment standart for advanced cervical cancer. The results of the COMPASSION-16 study were previously published in The Lancet and presented at the 2024 International Gynecologic Cancer Society (IGCS) Global Meeting. The Lancet publication and the IGCS presentation disclosed that cadonilimab, in combination with platinum-based chemotherapy (with or without bevacizumab), significantly extended survival in both PD-L1-positive and PD-L1-negative patient populations (mOS HR 0.64, P=0.0011), and reduced the risk of disease progression and death (mPFS HR 0.62, P<0.0001). At the 2025 ASCO annual meeting, the study's principal investigator, Professor Xiaohua Wu from the Fudan University Shanghai Cancer Center, presented the subgroup analysis findings from the COMPASSION-16 study, with data cut-off as of April 30, 2024. Key Findings: Significant Reduction in Mortality Risk Across All Patient Subgroups, Regardless of PD-L1 Expression: In the CPS<1 group, mPFS was 12 months in the cadonilimab arm vs. 8.2 months in the control arm (HR=0.65), and mOS was not reached in the cadonilimab arm vs. 25.3 months in the control arm (HR=0.77). In the CPS≥1 group, mPFS was 14.7 months in the cadonilimab arm vs. 8.3 months in the control arm (HR=0.62), and mOS was not reached in the cadonilimab arm vs. 22.7 months in the control arm (HR=0.69). In the CPS≥10 group, mPFS was 17.1 months in the cadonilimab arm vs. 8.1 months in the control arm (HR=0.54), and mOS was not reached in the cadonimab arm vs. 29 months in the control arm (HR=0.68). Clinical Benefit in PFS and OS Regardless of Prior CCRT Treatment: In patients previously treated with CCRT, mPFS was 16.1 months in the cadonilimab arm vs. 7.9 months in the control arm (HR=0.55), and mOS was not reached in the cadonilimab arm vs. 22.8 months in the control arm (HR=0.54). Clinical Benefit in PFS and OS Regardless of Bevacizumab Use: In real-world settings, approximately 40% of patients are considered unsuitable for bevacizumab due to underlying conditions or bleeding/perforation risks. Cadonilimab demonstrated clinically meaningful improvements in both PFS and OS, whether or not bevacizumab was included in the treatment. In the bevacizumab-naive groups, mPFS was 11.7 months in the cadonilimab arm vs. 6.7 months in the control arm (HR=0.44), and mOS was 28.2 months in the cadonilimab arm vs. 15.1 months in the control arm (HR=0.5). Improvement in PFS and OS Across Age Subgroups, with Greater Efficacy in Patients ≥65 Years: In patients < 65 years, mPFS was 13.5 months in the cadonilimab arm vs. 9.5 months in the control arm (HR=0.68), and mOS was not reached in the cadonilimab arm vs. 25.3 months in the control arm (HR=0.69). In patients ≥ 65 years, mPFS was 12 months in the cadonilimab arm vs. 7.4 months in the control arm(HR=0.39), and mOS was 26.6 months in the cadonilimab arm vs. 15.1 months in the control arm (HR=0.49). Cadonilimab Combined with Platinum Agents (Cisplatin/Carboplatin) Improves PFS and OS: In the cisplatin arm, mPFS was 14.7 months in the cadonilimab arm vs. 8.1 months in the control arm (HR=0.49), and mOS was not reached in the cadonilimab arm vs. 23.9 months in the control arm (HR=0.43). In the carboplatin arm, mPFS was 12 months in the cadonilimab arm vs. 8.2 months in the control arm (HR=0.72), and mOS was 27.8 months in the cadonilimab arm vs. 22.8 months in the control arm (HR=0.82). In June 2022, cadonilimab was granted approval by the China National Medical Products Administration (NMPA) for the treatment of recurrent or metastatic cervical cancer in patients who had previously failed platinum-based chemotherapy. This indication has since been included in the national reimbursement list. In September 2024, the use of cadonilimab in first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma was approved by the NMPA. The use of cadonilimab in first-line treatment for advanced, recurrent, or metastatic cervical cancer was approved by the NMPA in May 2025. In addition, cadonilimab is currently being evaluated in nearly 30 registrational/Phase III and Phase II clinical trials across a number of high-incidence cancers. Preliminary results show that cadonilimab demonstrates clinical benefit for patient populationsin both the positive and the negative PD-L1 expression groups, marking a significant advancement over existing immunotherapies. Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. ( 9926.HK, "Akeso") contains "forward-looking statements" . These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. SOURCE Akeso, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果临床3期上市批准ASCO会议临床2期

2025-06-16

·康方生物Akeso

重塑临床格局、填补临床空白丨卡度尼利一线治疗晚期宫颈癌亚组分析数据在ASCO 2025以Oral形式发布

近日，康方生物（9926.HK）自主研发的全球首创PD-1/CTLA-4双特异性抗体开坦尼®（卡度尼利单抗注射液）一线治疗持续、复发或转移性宫颈癌中的III期临床研究（COMPASSION-16）的亚组分析数据在2025年美国临床肿瘤学会年会上以口头报告形式重磅发表。COMPASSION-16研究亚组分析显示：无论PD-L1表达水平，既往是否接受同步放化疗（CCRT）、贝伐珠单抗使用情况以及年龄（≥65，＜65）等情况，亚组分析结果与总体人群的结果一致，卡度尼利治疗方案均极大改善了PFS和OS，再度强化了卡度尼利方案完全迭代晚期宫颈癌标准治疗的巨大临床价值和商业化潜力。COMPASSION-16研究成果全文已在《柳叶刀》和2024年国际妇科癌症学会全球会议中重磅报道，研究证实，卡度尼利联合含铂化疗（无论是否联合贝伐珠单抗）可显著延长一线晚期宫颈癌患者全人群（包括PD-L1表达阳性人群和阴性人群）的生存期（mOS HR 0.64，P=0.0011），显著降低了疾病进展与死亡风险（mPFS HR 0.62, P<0.0001）。吴小华教授本届ASCO大会中，主要研究者、复旦大学附属肿瘤医院吴小华教授进一步口头汇报了COMPASSION-16的亚组分析结果（数据截止日期为2024年4月30日）。无论PD-L1表达，卡度尼利方案显著降低全人群患者死亡风险：在CPS＜1人群，mPFS分别是12个月vs 8.2个月，HR=0.65；mOS分别为NA vs 25.3个月，HR=0.77。这一数据提示，卡度尼利方案充分弥补CPS＜1人群在免疫药物疗效受限、获益不足/无获益的临床困境，填补PD-L1阴性宫颈癌患者的免疫治疗空白。在CPS≥1人群，mPFS分别是14.7个月vs 8.3个月,HR=0.62；mOS分别为NA vs 22.7个月，HR=0.69；在CPS≥10人群，mPFS分别是17.1个月vs 8.1个月,HR=0.54；mOS分别为NA vs 29个月，HR=0.68；无论既往是否接受过CCRT治疗，卡度尼利方案的PFS和OS均显示出具有临床意义的获益：CCRT经治患者的mPFS 分别是16.1个月vs 7.9个月，HR=0.55；mOS分别是NA vs 22.8个月，HR=0.54。无论是否联合贝伐珠单抗，卡度尼利方案的PFS和OS均显示出具有临床意义的获益：真实世界中，约40%的患者被认为不适合使用贝伐单抗（如因基础疾病或出血/穿孔风险）。卡度尼利在无进展生存期（PFS）和总生存期（OS）方面均带来具有临床意义的改善。不联合贝伐珠单抗患者的mPFS分别为11.7个月vs 6.7个月，HR=0.44；mOS分别为28.2个月vs 15.1个月，HR=0.5。卡度尼利在不同年龄的患者中均能改善PFS和OS，且在年龄≥65岁的患者中效果更为显著：＜65岁的患者mPFS 分别是13.5个月vs 9.5个月，HR=0.68；mOS分别是NA vs 25.3个月，HR=0.69。≥65岁的患者mPFS 分别是12个月vs 7.4个月，HR=0.39；mOS分别是26.6 vs 15.1个月，HR=0.49。卡度尼利联合铂类药物（卡铂/顺铂）均能改善PFS和OS：联合顺铂患者的mPFS分别是14.7个月vs 8.1个月，HR=0.49；mOS分别是NA vs 23.9个月，HR=0.43；联合卡铂患者的mPFS分别是12个月vs 8.2个月，HR=0.72；mOS分别是27.8个月vs 22.8个月，HR=0.82。宫颈癌是常见且发病率较高的女性肿瘤，晚期宫颈癌5年生存率仅约17.0%。相关数据显示，中国2022年宫颈癌新发病例15.07万，死亡病例5.57万，为世界第二大宫颈癌疾病负担国。2022年6月，卡度尼利已获得中国国家药品监督管理局（NMPA）批准用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者，填补了中国晚期宫颈癌免疫治疗的空白，目前该适应症已纳入国家医保目录。2024年9月，卡度尼利联合标准治疗方案一线治疗晚期胃癌适应症获得CDE批准，卡度尼利方案一线治疗持续、复发或转移性宫颈癌适应症也在2025年5月获NMPA批准上市。与此同时，卡度尼利已针对多种高发瘤种疾病开展了近30项注册性/III期临床和II期临床研究，相关临床研究结果显示，卡度尼利针对全人群（无论PD-L1表达，包括阳性和阴性）均具有临床突破性潜力，展现了针对当前免疫疗法具有显著的代际差价值。说明：本文作为康方生物的新闻发布，用于披露公司最新进展，并非产品推广广告，不构成康方生物的信息披露或投资建议。关于开坦尼®（卡度尼利单抗注射液）开坦尼®是康方生物自主研发的全球首创PD-1/CTLA-4双特异性肿瘤免疫治疗药物，2022年6月获得国家药品监督管理局的批准，用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗。2024年9月，开坦尼®联合方案用于局部晚期不可切除或转移性胃或胃食管结合部（G/GEJ）腺癌患者一线治疗适应症获批；2025年5月，开坦尼®加含铂化疗联合/不联合贝伐珠单抗一线治疗持续、复发或转移性宫颈癌的适应症获批。开坦尼®是世界上第一个肿瘤免疫治疗双抗新药，也是中国的第一个双特异性抗体新药。开坦尼®既往接受含铂化疗失败的复发或转移性宫颈癌适应症于2024年11月被纳入2024年国家医保目录。开坦尼®已针对胃癌、肺癌、肝癌、宫颈癌、胰腺癌等16种恶性肿瘤疾病开展了30项以上的临床研究。开坦尼®是一种全新机制的肿瘤免疫治疗药物，可以同时靶向PD-1和CTLA-4发挥协同抗肿瘤的作用，具有优异的抗肿瘤疗效，相比联合疗法的毒性显著降低，安全可耐受。多项临床研究显示，开坦尼®针对多种肿瘤疾病的PD-L1表达阳性和阴性患者均具有优异的抗肿瘤疗效，临床差异化价值凸显。目前，开坦尼®已被16项临床治疗指南和共识重磅推荐，覆盖胃癌、妇科肿瘤、肝癌、食管癌、鼻咽癌等多个适应症。关于康方生物康方生物（9926.HK）是一家集研究、开发、生产及商业化全球首创或同类最佳创新生物新药于一体的领先企业。自2012年成立以来，公司始终以患者为中心，以临床价值为导向，打造了独有的端对端康方全方位新药研究开发平台，建立了以Tetrabody双特异性抗体开发技术、抗体偶联（ADC）技术、mRNA技术及细胞治疗技术为核心的研发创新体系，国际化标准的GMP生产体系和运作模式先进的商业化体系，成为了在全球范围内具有竞争力的生物医药创新公司。公司已开发了50个以上用于治疗肿瘤、自身免疫、炎症、代谢疾病等重大疾病的创新候选药物，24个候选药已进入临床（包括15个双抗/多抗/双抗ADC），7个新药已在商业化销售，2个新药2个适应症的上市申请处于审评审批阶段。康方生物是全球迄今唯一拥有2个肿瘤免疫双抗新药的制药公司：2022年6月，公司全球首创的PD-1/CTLA-4双抗开坦尼®获批上市，是全球首个获批的肿瘤免疫治疗双抗新药，也是中国第一个双特异性抗体新药。目前开坦尼®一线治疗胃癌、一线治疗宫颈癌和治疗复发/转移性宫颈癌适应症已获批，8个注册性/III期临床已开展。2024年5月，公司另一全球首创双抗新药依达方®获批上市，用于EGFR-TKI治疗进展的局部晚期或转移性nsq-NSCLC，是全球首个获批的“肿瘤免疫+抗血管生成”机制双抗新药。同期，依达方®在与全球“药王”帕博利珠单抗的随机、双盲、对照一线治疗PD-L1阳性NSCLC的“头对头”III期临床研究中获得显著阳性结果，依达方®可降低患者疾病进展/死亡风险达49%，依沃西成为全球首个在头对头III期临床研究中证明疗效显著优于“药王”帕博利珠单抗的药物。基于该研究结果，依沃西同适应症的sNDA于2025年4月获批上市，成为一线肺癌治疗新的标准治疗方案，为患者提供全新更优的“去化疗”选择。目前依达方®有12项注册性/III期临床已开展，包括3项国际多中心注册性III期临床研究。2024年12月，开坦尼®、依达方®均通过医保谈判被纳入国家新版医保目录。国际市场开发是康方生物核心发展战略，继2015年开中国先河将自主研发的CTLA-4单抗权益许可给默沙东公司之后，2022年12月，公司再次创造中国记录，以50亿美金+2位数百分比销售提成的方案，将依达方®部分海外权益许可给美国Summit公司，该合作创下了彼时中国新药对外许可的最高交易金额记录。2025年2月，Summit 与美国辉瑞（Pfizer）公司达成临床试验合作，共同推进依达方®联合辉瑞多款抗体偶联药物（ADCs）在多种实体瘤中的联合治疗疗法。安尼可®联合方案一线治疗转移性鼻咽癌和单药用以铂类为基础的化疗治疗失败的转移性鼻咽癌两项适应症于2025年4月获得美国食品药品监督管理局（FDA）批准上市。2024年9月，公司自主研发的伊喜宁®（伊努西单抗，PCSK9）治疗高胆固醇血症两项适应症获批，成为非肿瘤领域的首个获批产品。2025年4月，公司独立自主研发的爱达罗®（依若奇单抗，IL-12/IL-23“双靶向”单抗）获得批准上市，用于中重度斑块状银屑病成人患者的治疗。公司非肿瘤领域的产品协同效应和战略组合力进一步提升。康方生物期望通过高效及突破性的研发创新，开发国际首创及同类药物最佳疗法的新药，为全球患者提供更优疾病解决方案，成为全球领先的生物制药企业。往期推荐产品动态一线宫颈癌全人群获批！康方生物开坦尼®获批第三项适应症产品动态依沃西一线治疗NSCLC获批上市（全球首个对比帕博利珠单抗获显著阳性结果的III期研究）产品动态美国重磅上市！派安普利单抗2个适应症获FDA批准上市，用于晚期鼻咽癌治疗产品动态康方生物爱达罗®（依若奇,IL-12/IL-23）治疗中重度斑块状银屑病适应症获批上市临床进展首个自研ADC澳洲临床入组！康方生物IO 2.0+ADC战略再进一步临床进展非肿瘤首个双抗|康方生物全球首创IL-4Rα/ST2（AK139）IND获受理，剑指呼吸系统及皮肤疾病领域临床进展依沃西方案对比替雷利珠方案1L治疗sq-NSCLC的Ⅲ期临床完成患者入组临床进展康方生物古莫奇（IL-17）单抗新药上市申请获NMPA受理数据发布荣登Nature Medicine！卡度尼利方案1L治疗胃癌Ⅲ期研究结果全文发表产品动态康方生物卡度尼利、依沃西纳入2024年国家医保目录临床进展头对头度伐利尤单抗方案，依沃西方案一线治疗胆道肿瘤III期临床完成首例患者入组临床进展全球首个CD47单抗实体瘤III期临床首例入组：依沃西联合莱法利一线治疗HNSCC（对比帕博利珠单抗）数据发布卡度尼利一线宫颈癌III期研究成果荣登《Nature Reviews Clinical Oncology》（影响因子高81.1）数据发布IGCS 2024 LBA & 《柳叶刀》主刊，卡度尼利1L宫颈癌III期研究PFS和OS双阳性结果重磅发布产品动态获FDA快速通道资格！依沃西国际多中心III期研究HARMONi完成入组，2L+EGFRm NSCLC数据发布全球首个对比帕博利珠单抗取得显著阳性结果的随机对照大III期研究——依沃西HARMONi-2重磅研究成果在WCLC发表临床进展康方生物卡度尼利联合方案治疗uHCC的III期临床研究完成首例患者入组临床进展针对PD-1/L1治疗进展晚期胃癌，卡度尼利+普络西（VEGFR-2）联合疗法Ⅲ期临床完成首例入组数据发布ASCO Oral & JAMA主刊丨Ⅲ期HARMONi-A研究重磅公布，依沃西疗法有望改变EGFR-TKI进展肺癌全球治疗标准临床进展史无前例！康方依沃西单药对比帕博利珠1L治疗PD-L1阳性NSCLC的III期临床获决定性胜出阳性结果产品动态康方生物双抗卡度尼利一线治疗晚期宫颈癌全人群的sNDA获CDE受理临床进展国际多中心注册性III期研究HARMONi-3中国启动：依沃西单抗联合化疗对比帕博利珠单抗联合化疗1L治疗sq-NSCLC产品动态高达50亿美金！康方生物与Summit就PD-1/VEGF双抗依沃西达成合作和许可协议产品动态全球首个肿瘤免疫治疗双抗——开坦尼®（PD-1/CTLA-4双抗，卡度尼利）获批上市

临床结果ASCO会议临床3期免疫疗法

100 项与卡度尼利单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12190	-	-	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
晚期胃癌	中国	康方药业有限公司	2024-09-26
晚期胃食管交界处腺癌	中国	康方药业有限公司	2024-09-26
转移性宫颈癌	中国	康方药业有限公司	2022-06-28
复发性宫颈癌	中国	康方药业有限公司	2022-06-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃食管交界处腺癌	申请上市	中国	中山康方生物医药有限公司	2024-01-05
非小细胞肺癌 III期	临床3期	中国	中山康方生物医药有限公司	2024-11-12
转移性非小细胞肺癌	临床3期	中国	中山康方生物医药有限公司	2023-11-14
鳞状非小细胞肺癌	临床3期	中国	中山康方生物医药有限公司	2023-11-14
鼻咽癌	临床3期	中国	康方药业有限公司	2023-08-01
肝细胞癌	临床3期	中国	中山康方生物医药有限公司	2022-12-14
局部晚期宫颈癌	临床3期	中国	中山康方生物医药有限公司	2022-06-08
局部晚期胃食管交界处腺癌	临床3期	中国	中山康方生物医药有限公司	2021-09-17
局部晚期不可切除的胃腺癌	临床3期	中国	中山康方生物医药有限公司	2021-09-17
子宫颈转移癌	临床3期	中国	中山康方生物医药有限公司	2021-08-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO_ELCC2025	N/A	进行性非小细胞肺癌	70	Cadonilimab alone	膚蓋艱鏇醖齋齋鬱鬱鹽(願襯築廠顧鹹積襯壓醖) = 願網選選遞廠鬱簾積廠獵築築遞鹹鹹鹽憲選觸 (糧蓋襯糧築鹹網鑰築範 ) 更多	积极	2025-03-26
NCT05235516 (AK104-305 \| COMPASSION-18, Company_Website) 人工标引	临床3期	局部晚期宫颈癌	-	AK104 + CCRT	憲齋窪衊衊醖齋繭壓鬱(遞範壓鏇衊鹽鑰夢廠願) = 廠蓋窪鹹廠襯願願艱窪繭遞觸積簾鏇鑰齋積製 (壓糧餘鏇糧觸顧膚夢蓋 ) 更多	积极	2025-03-21
				AK104 + CCRT (PD-L1 CPS≥1)	夢繭鹹醖憲窪襯淵餘醖(積觸顧鹹憲餘鏇襯獵蓋) = 鏇衊餘夢網壓鹽願鬱淵觸觸鏇夢衊選壓壓獵獵 (夢鹽鑰製鹽遞繭鹹餘積 )
NCT05792735 (NeoCaCRT, ASCO_GI2025) 人工标引	临床2期	局部晚期直肠癌新辅助 Proficient DNA Mismatch Repair (pMMR) \| Microsatellite Stable (MSS)	27	SCRT + Cadonilimab + mFOLFOX6	構網願鏇窪網積積獵範(繭憲選衊憲積壓繭鏇窪) = 觸醖簾觸餘窪鹽夢鏇簾鏇鏇窪淵淵遞製簾夢獵 (選蓋憲選繭鑰製獵糧製, 19.4 ~ 57.6) 更多	积极	2025-01-23
NCT05522894 (AK104-IIT-014, ASCO_GI2025) 人工标引	临床2期	晚期食管鳞状细胞癌维持 \| 一线	43	Cadonilimab + Paclitaxel + Cisplatin	觸構鬱廠繭鹹遞醖襯壓(鹽網壓窪構餘網觸壓簾) = 構糧鑰顧鏇窪壓蓋夢製鬱夢觸願醖膚糧簾夢窪 (繭膚膚範顧餘憲鹹範鹹, 66.1 ~ 91.1) 更多	积极	2025-01-23
				Cadonilimab + Paclitaxel + Cisplatin (PD-L1 CPS≥10)	觸構鬱廠繭鹹遞醖襯壓(鹽網壓窪構餘網觸壓簾) = 積膚膚衊顧襯壓鏇積衊鬱夢觸願醖膚糧簾夢窪 (繭膚膚範顧餘憲鹹範鹹, 77.1 ~ 100.0) 更多
NCT05008783 (Pubmed) 人工标引	临床3期	HER2阴性胃癌 \| HER2阴性胃食管结合部腺癌一线 HER2 Negative	610	Cadonilimab + Chemotherapy	顧製網觸簾襯蓋遞糧顧(衊鹽願鹽廠壓範鏇襯鹹) = 齋鹽淵窪遞觸齋築觸繭製選艱範積鏇築蓋糧願 (夢築製糧膚鬱獵餘壓窪 ) 达到更多	积极	2025-01-22
				Placebo + Chemotherapy	顧製網觸簾襯蓋遞糧顧(衊鹽願鹽廠壓範鏇襯鹹) = 鬱鏇鏇選襯衊鹽壓鑰網製選艱範積鏇築蓋糧願 (夢築製糧膚鬱獵餘壓窪 ) 达到更多
NCT05815290 (ESMO_IO2024) 人工标引	临床2期	错配修复缺陷或微卫星高度不稳定性结直肠癌新辅助 MSI-High \| Deficient DNA Mismatch Repair (dMMR)	34	Cadonilimab (AK104) 10mg/kg	夢糧蓋鹽艱範鏇獵鬱觸(築廠範糧製窪鏇壓鏇衊) = 餘膚窪夢艱選鑰鑰顧鏇襯鏇網範窪範積範襯夢 (醖壓網選觸蓋觸齋淵繭 ) 更多	积极	2024-12-12
NCT05430906 (AK104-IIT-003, ESMO_IO2024) 人工标引	临床2期	卵巢癌新辅助	28	Cadonilimab + Platinum-Taxane Chemotherapy	齋壓齋夢憲築遞襯鬱願(鏇艱觸壓構襯獵築醖鹽) = 鹹襯衊鏇襯衊鹽衊繭廠網壓繭願淵積鏇觸壓壓 (蓋夢構糧憲廠繭獵鑰遞 ) 更多	积极	2024-12-12
ESMO_IO2024 人工标引	N/A	转移性非小细胞肺癌二线 \| 末线 \| 三线	21	Cadonilimab (AK104) + Single-agent Chemotherapy	夢窪築顧製衊簾襯襯窪(顧憲憲壓鏇觸網醖憲鹹) = 窪蓋鏇繭餘構範鏇鏇構餘窪繭獵鏇齋衊艱遞淵 (鹹襯築築鏇鬱夢鑰廠鹽 ) 更多	积极	2024-12-12
ESMO_IO2024 人工标引	临床2期	晚期胃癌 \| 晚期胃食管交界处腺癌一线	19	Cadonilimab+SOX (HER2-negative)	製醖夢艱製糧壓選觸齋(壓壓範鑰構鹹範遞構願) = 顧構顧築構鏇憲衊膚夢廠構構餘範膚觸窪築選 (齋鏇窪廠蓋範蓋簾蓋艱 ) 更多	积极	2024-12-12
				Cadonilimab+Trastuzumab+SOX (HER2-positive)	製醖夢艱製糧壓選觸齋(壓壓範鑰構鹹範遞構願) = 顧餘簾蓋夢網醖網網襯廠構構餘範膚觸窪築選 (齋鏇窪廠蓋範蓋簾蓋艱 ) 更多
ESMO_IO2024 \| NEWS 人工标引	N/A	转移性胃食管结合部腺癌 \| 转移性胃腺癌一线	31	Cadonilimab plus chemotherapy (SOX, XELOX or FOLFOX)	襯鹽築壓築製醖鑰選憲(餘顧糧獵簾夢顧壓糧積) = 蓋壓遞廠築蓋獵遞顧廠醖顧淵簾淵積淵製淵鹹 (繭憲廠遞齋憲鏇遞鑰壓 ) 更多	积极	2024-12-12
				Cadonilimab plus chemotherapy (SOX, XELOX or FOLFOX) (PD-L1 CPS＜1)	襯鹽築壓築製醖鑰選憲(餘顧糧獵簾夢顧壓糧積) = 願觸襯構選構艱選壓壓醖顧淵簾淵積淵製淵鹹 (繭憲廠遞齋憲鏇遞鑰壓 ) 更多